TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections. Continue reading New Drug to Help with Resistant Fungal Lung Infections
The hope is that DNA sequencing burkholderia bacteria that cause life-threatening infections in cystic fibrosis patients will lead to cheaper treatment options. Continue reading UBC research uses genomics to help cystic fibrosis patients
AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis
• TREATMENT WITH AEOL 20415 REDUCED INFECTION, IMPROVED BODY WEIGHT AND REDUCED PRESENCE OF WHITE Continue reading Animal model with CF shows promise against infection
New antibiotic from bacteria found on Kenyan ant could help beat MRSA
A new antibiotic, produced by bacteria found on a species of African ant, is very potent against antibiotic-resistant ‘superbugs’ like MRSAaccording to scientists.
Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) discovered a new member of the Streptomyces bacteria family, isolated from the African fungus-growing plant-ant Tetraponera penzigi. They have named the new species Streptomyces formicae and the antibiotics formicamycins, after the Latin formica, meaning ant.
Lab tests have shown these new antibiotics are effective against methicillin resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococci (VRE), bacteria which are resistant to a number of common antibiotics and can cause life-threatening infections.
Almost all of the antibiotics currently in clinical use come from a group of bacteria called actinomycetes that were isolated from soil between 40-80 years ago, the ‘golden age’ of antibiotic discovery. Inappropriate use of these antibiotics since then has led to widespread antimicrobial resistance (AMR), where disease-causing bacteria and fungi have become resistant to one or more antibiotics.
Prof Matt Hutchings from UEA said: “We have been exploring the chemical ecology of protective symbioses formed between antibiotic-producing bacteria and fungus-growing insects to better understand how these associations are formed and explore them as a new source of anti-infective drugs.
“Kenyan plant-ants live in symbiosis with thorny acacia trees. They live and breed in domatia – which are hollowed out structures which the plant evolved to house them – and grow fungus in them for food. In return, they protect the plants from large herbivores including elephants, which won’t eat plants covered in ants.”
The team isolated a number of actinomycete bacterial strains from the acacia plant housing the ants, selecting a number for genome sequencing. One particular strain caught their attention, and the antibiotic compounds produced from it showed promising activity in early tests against other disease-causing bacteria.
Prof Hutchings said: “We tested formicamycins against clinical isolates of MRSA and vancomycin-resistant Enteroccocus faecium (VRE) and found that they are very potent inhibitors of these organisms.”
To test this further, they repeated the tests by growing the strains for 20 generations in very low, sub-inhibitory concentrations of formicamycins and found no sign that the test strains acquired spontaneous higher level resistance to the new antibiotics.
Prof Wilkinson from JIC said: “Our findings highlight the importance of searching as-yet under-explored environments, which, when combined with recent advances in genome sequencing and editing, enables the discovery of new species making natural product antibiotics which could prove invaluable in the fight against AMR.”
Article: Formicamycins, antibacterial polyketides produced by Streptomyces formicae isolated from African Tetraponera plant-ants, Zhiwei Qin, John T Munnoch, Rebecca Devine, Neil A Holmes, Ryan Seipke, Karl A Wilkinson, Barrie Wilkinson and Matthew Hutchings , Chemical Science, doi: 10.1039/C6SC04265A, published online 13 February 2017.
I’m not naïve enough to think that I’m going to wake up tomorrow and find that my life is moving forward with cystic fibrosis in the rearview mirror.
We’re still a little bit away from that moment, but that doesn’t mean I don’t have high expectations for treatment development. Continue reading My Wish List for the New Year By Gunnar Esiason
Agile Sciences in Raleigh, NC has developed a potentially powerful, effective and affordable means to stem the tide of antibiotic resistance. Results show that their proprietary family of 2 Amino-Imadazole (2-AI) compounds, act directly on the Continue reading Agile Sciences Creates A Powerful New Weapon In The Fight Against Antibiotic Resistance
So… there have been some pretty big news headlines the past few days. Between gorillas, a kid calling the police to report his dad going through a RED LIGHT and the Florida Panthers appeasing their fan base of 15 with new logos and jerseys, last week was pretty crazy. Continue reading OWN IT: MCR-1 is Here
A potential drug therapy developed at the University of Pittsburgh Center for Vaccine Research (CVR) has proven effective against tough bacterial biofilms and a deadly respiratory virus simultaneously. The drug outperforms Continue reading Antibiotic Against Superbug Biofilms, RSV
Recent research progress into how bacteria adapt and evolve during chronic lung infections in cystic fibrosis patients could lead to better treatment strategies being developed, according to a new review by the University of Continue reading Evolving insights into cystic fibrosis lung infections